SCHEMBL4336211

SCHEMBL4336211

NC(=S)N/N=C/c1ccc(N2CCCN(Cc3c(F)cccc3Cl)CC2)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
PKM P14618 2/20 0.43
GAA P10253 1/20 0.43
MAOB P27338 1/20 0.43
POLB P06746 2/20 0.41
ALDH1A1 P00352 3/20 0.40
PHGDH O43175 1/20 0.40
ALOX12 P18054 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD11B1 P28845 1/20 0.40
CYP2A13 Q16696 1/20 0.40
GPR6 P46095 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
ALOX15 P16050 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336214 1.00 LMNA (0.43) LMNAPKMGAAMAOBPOLB
SCHEMBL4459417 0.96 LMNA (0.42) LMNAPKMGAAMAOBPOLB
SCHEMBL4459412 0.96 LMNA (0.42) LMNAPKMGAAMAOBPOLB
SCHEMBL4331940 0.93 LMNA (0.43) LMNAPKMGAAMAOBPOLB
SCHEMBL4331934 0.93 LMNA (0.43) LMNAPKMGAAMAOBPOLB
SCHEMBL4325107 0.92 MAOB (0.45) LMNAPKMMAOBPOLBALDH1A1
SCHEMBL4325104 0.92 MAOB (0.45) LMNAPKMMAOBPOLBALDH1A1
SCHEMBL4329141 0.92 GPR6 (0.41) LMNAPKMGAAMAOBPOLB
SCHEMBL4341458 0.92 LMNA (0.40) LMNAPKMGAAMAOBPOLB
SCHEMBL4329131 0.92 GPR6 (0.41) LMNAPKMGAAMAOBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 LMNA 4884/4885PKM 4105/4885GAA 2113/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 LMNA 4885/4885PKM 4038/4885GAA 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.